Background Antiviral therapy should reduce the recurrence of hepatitis B virus‐related
hepatocellular carcinoma (HBV‐related HCC) after surgical resection. However, there is little …

Background Postoperative oral antiviral treatment with nucleoside or nucleotide analogues
can suppress viral replication and reduce tumour recurrence for patients with hepatitis b …

Background and aim Studies suggest that antiviral therapy performed after curative
resection improves the postoperative prognosis of hepatitis B virus (HBV)-related …

Aim To examine the effect of nucleoside analog (NA) therapy on clinical outcome in patients
with hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC) who underwent …

Objective: The purpose of this study was to evaluate the efficacy of different nucleos (t) ide
analogues in the prognosis of HBV-related hepatocellular carcinoma (HCC) patients after …

Background and objective A systematic review was conducted to evaluate whether or not
antiviral therapy with nucleotide/nucleoside analogs (NA) have survival benefit for patients …

Background The long-term outcome after curative resection of hepatocellular carcinoma
(HCC) remains unsatisfactory because of the high incidence of recurrence. The present …

Background: Nucleot (s) ide analog treatment (entecavir (ETV) and tenofovir (TDF)) is
reported to be associated with decreased tumor recurrence and death in hepatitis B virus …

Abstract Background and Aim The efficacy of nucleoside analogs (NAs) for hepatitis B virus
(HBV)-related hepatocellular carcinoma (HCC) after curative treatment remains unclear. The …

The outcome after curative resection for hepatocellular carcinoma (HCC) remains
unsatisfactory due to the high recurrence rate after surgery. In patients with hepatitis B virus …